What did @simidoctors actually say?
The creator warns that retatrutide, a triple-receptor weight loss drug still in clinical trials, is being ordered online from compounding pharmacies before its safety profile is fully established. They cite phase 2 trial data showing "people losing up to 60 pounds in the first year," mention it targets GLP-1, GIP, and glucagon receptors, and flag specific concerns: a 14% rate of cardiac arrhythmias compared to placebo, potential bone loss, and increased liver load. Their bottom line is a caution against self-administering an unapproved drug with incomplete long-term safety data. That's a reasonable position to take. The framing is mostly responsible, though some of the numbers and mechanisms need scrutiny.
Does the science back this up?
Partially, yes. The phase 2 trial data is real and the weight loss numbers are striking. The Jastreboff et al. (2023, NEJM) phase 2 trial of retatrutide showed dose-dependent weight reduction of up to 24.2% of body weight at 48 weeks in the highest dose group, which does translate to roughly 50-60 pounds in heavier participants. The triple-agonist mechanism targeting GLP-1, GIP, and glucagon receptors is accurately described. The cardiac safety signal is where things get more complicated. The NEJM trial did report higher rates of heart rate elevation and some arrhythmia signals, but the specific "14% arrhythmia compared to placebo" figure needs more context than it was given. Bone density concerns in triple agonists are plausible given glucagon receptor activity and rapid fat turnover, but this remains under investigation. The liver normalization claim around fatty liver is supported by early NASH-related findings in the data, though 86% is a figure that deserves a source citation.
What did they get wrong (or right)?
They got the big picture right: retatrutide is not approved, phase 3 trials are ongoing, and people ordering it online from compounding pharmacies are taking on unquantified risk. Credit where it's due.
Where it gets shakier:
- The "14% arrhythmia" figure is imprecise. The Jastreboff 2023 NEJM data reported elevated heart rate as an adverse event, and some arrhythmia-related findings, but presenting a single percentage without specifying the dose group, the arrhythmia type, or whether it was symptomatic versus detected on monitoring is misleading. Listeners will hear "14% chance of heart problems" when the actual picture is more nuanced.
- Calling it "the most powerful drug in weight loss history" is marketing language, not a clinical claim. Tirzepatide already showed 22.5% body weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). Retatrutide's advantage is real but incremental at this stage of evidence.
- The glucagon receptor is described as something that "increases your metabolism," which is a simplification. Glucagon agonism increases hepatic glucose output and lipolysis, but framing it simply as a metabolism booster omits the mechanistic complexity that explains why liver load is a legitimate concern.
What should you actually know?
Retatrutide is not FDA-approved. It is not available as a legal prescription drug. Any compound being sold online and labeled as retatrutide has no regulatory oversight for purity, concentration, or sterility. Compounded drugs are not equivalent to investigational drugs being studied in controlled clinical settings, and that gap matters enormously when the safety profile is still being written.
The phase 3 trials are ongoing as of 2024. That means the long-term cardiovascular, bone, and hepatic data does not yet exist in published form. The phase 2 findings are promising for efficacy, but phase 2 trials are not powered or designed to detect rare serious adverse events. Cardiac arrhythmias in the context of rapid weight loss and metabolic shift are a known area of concern across GLP-class drugs, and the glucagon component adds a layer that hasn't been seen in approved agents yet.
If you are interested in GLP-based therapies for weight management, there are FDA-approved options with established safety data. A telehealth provider can help you evaluate whether those are appropriate for your situation. Injecting an uncharacterized compound purchased online is a different category of decision entirely.